GET THE APP

Drug Designing: Open Access

Drug Designing: Open Access
Open Access

ISSN: 2169-0138

+44 1223 790975

Drug Designing: Open Access : Citations & Metrics Report

Articles published in Drug Designing: Open Access have been cited by esteemed scholars and scientists all around the world. Drug Designing: Open Access has got h-index 9, which means every article in Drug Designing: Open Access has got 9 average citations.

Following are the list of articles that have cited the articles published in Drug Designing: Open Access.

  2021 2020 2019 2018 2017 2016

Year wise published articles

31 67 2 5 16 18

Year wise citations received

50 43 38 38 22 46
Journal total citations count 368
Journal impact factor 1.70
Journal 5 years impact factor 1.5
Journal cite score 1.57
Journal h-index 9
Journal h-index since 2018 7
Important citations (297)

Role of vegetables in human nutrition and disease prevention

Functional relationship of vegetable colors and bioactive compounds: implications in human health

Pegylation enhances the antibacterial and therapeutic potential of amphibian host defence peptides.

Cell-penetrating peptides in oncologic pharmacotherapy: a review.

The roles of fatty-acid modification in the activity of the anticancer peptide r-lycosin-i.

G�³mez y, gonz�¡lez m, hern�¡ndez d, arag�³n h, vallespi mg. monoclonal antibodies for the cigb-552 antitumor synthetic peptide quantification. j vet sci ani husb. 2019; :101.

In vitro selective suppression of tumor cells by an oncolytic peptide in pancreatic ductal adenocarcinoma

Structure-activity relationship studies of longicalcynin a analogues, as anticancer cyclopeptides.

An integrative approach discovers a novel anti-leukemic peptide from human milk

Hmp-s7 is a novel anti-leukemic peptide discovered from human milk.

Evaluation of anti-cancer and anti-covid-19 properties of cationic pentapeptide glu-gln-arg-pro-arg, from rice bran protein and its d-isomer analogs through molecular docking simulations.

Peptide-based therapeutics for oncology

Two decades of research in discovery of anticancer drugs targeting stat3, how close are we?

Signal transducer and activator of transcription protein 3 (stat3): an update on its direct inhibitors as promising anticancer agents

Chen x, guo l, ma q, chen w, fan w, zhang j. design, synthesis, and biological evaluation of novel n-acylhydrazone bond linked heterobivalent β-carbolines as potential anticancer agents. molecules. 2019;24 :2950.

Deokar h, deokar m, wang w, zhang r, buolamwini jk. qsar studies of new pyrido [3, 4-b] indole derivatives as inhibitors of colon and pancreatic cancer cell proliferation. medicinal chemistry research. 2018 ;27: 2466-81.

Peltek oo, muslimov ar, zyuzin mv, timin as. current outlook on radionuclide delivery systems: from design consideration to translation into clinics. journal of nanobiotechnology. 2019;17: 90.

Kang kw, song mg. organic nanomaterials: liposomes, albumin, dendrimer, polymeric. radionanomedicine: combined nuclear and nanomedicine. 2018: 105.

Dias ap, da silva santos s, da silva jv, parise filho r, ferreira ei, el seoud o, et al. dendrimers in the context of nanomedicine. international journal of pharmaceutics. 2019 : 118814.

Kang kw, song mg. organic nanomaterials: liposomes, albumin, dendrimer, polymeric nanoparticles. inradionanomedicine 2018.

Top